A Study of LY3200882 in Participants With Solid Tumors

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02937272.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationEli Lilly and Company

• Primary ID16185
• Secondary IDsNCI-2017-00056, 2016-001431-12, I8X-MC-JECA
• ClinicalTrials.gov IDNCT02937272